NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Impact BioMedical Inc. (IBO) Stock Analysis

Impact BioMedical Inc. (IBO) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

IBO

$0.54

+$0.06 (+12.50%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IBO with… →

IBO Key Statistics

As of Sep 4, 2026
Trading
Open
$0.48
Previous Close
$0.48
Day's Range
0.47–0.64
52-Week Range
0.37–0.83
Volume
4.12M
Valuation
Market Cap
$58.22M
P/E Ratio
0.55
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1663.53
EPS (ttm)Profit attributable to each share over the last twelve months.
0.99
Financials (FY)
Revenue (FY)
$32.00K
Net Income (FY)
−$11.84M
Profit marginThe share of revenue left as profit after all costs and taxes.
2260.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
107.82M
1-Year Return
−7.38%
Dividend and dates
Avg Volume
51.48K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IBO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+6.93%
2025−65.17%
2024 (partial year)−45.90%

As of September 4, 2026.

IBO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$32.00K−$11.84M−36993.8%
2024$0.00−$24.71M—
2023$0.00−$4.34M—
2022$50.00K−$7.05M−14102.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$32.00K−$392.00K−$4.27M−$11.84M−36993.8%
2024$0.00$0.00−$3.40M−$24.71M—
2023$0.00—−$4.03M−$4.34M—
2022$50.00K—−$3.40M−$7.05M−14102.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IBO Valuation vs Biotechnology Median

Median of 656 stocks
MetricIBOBiotechnology medianvs median
P/E0.5512.570.0x the median
P/S ratio1663.5315.26109.0x the median
Profit margin2260.00%0.00%2260.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Impact BioMedical Inc. (IBO) is capitalised at $58.22M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 2 employees.

The 52-week range on file runs from $0.37 to $0.83. IBO last closed at $0.54 on September 4, 2026. That is +$0.06 (+12.50%) against the previous close. The latest close sits 45.95% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $32.00K. The same year closed with a net loss of $11.84M. Profit margin runs at 2,260%. That is 2,260 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 0.99.

Across the 4 fiscal years on file, revenue moves from $50.00K in 2022 to $32.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 0.55. That is 0 times the Biotechnology median of 12.57. The price-to-sales ratio is 1,663.53. On price-to-sales that is 109 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Annualized volatility over the trailing 2 years is 381.04%. The trailing one-year price return is −7.38%. The stored price history starts on September 16, 2024, and the total return since then is −79.85%.

Growth & Income

No dividend is on file for IBO.

2026 is still running; the price is +6.93% year to date. The record holds one complete calendar year, 2025, which returned −65.17%.

Peer Comparison

Impact BioMedical Inc. (IBO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Impact BioMedical Inc. IBO $58.22M 0.6
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Impact BioMedical Inc. trades at a P/E of 0.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Impact BioMedical Inc.

Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc

Visit website →